Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just because you and Roy believe Dax is a superior product does not mean that injectors and every patient shares that belief.
That has to happen before the company runs out of money. Until profitability is absolutely certain, putting money into this company as an investor is a very risky speculation in my opinion.
You may be right. In which case, you’ll become a multimillionaire and my net worth won’t grow as much as it could’ve.
But I will not die broke.
Thank you for your concern.
Nevertheless it’s completely unwarranted.
If I never receive another penny of income nor earn any amount from my stocks, I assure you I will never die broke.
LOL
You might die broke if you continue wasting your time to post on a stock board that you have nothing to do with LOL
Just because you and Roy believe Dax is a superior product does not mean that injectors and every patient shares that belief.
No matter how many times you and everyone else post its superiority on this board, injectors, and the patients will continue to believe what they have always believed.
Once the treating community and those requiring treatment are convinced, the sales should increase steadily. I suspect the abject failure of the initial launch at higher (premium) prices will continue to impact the anticipated growth . That is, potential patients who paid dearly and got atrocious treatment are probably still pissed off.
That has to happen before the company runs out of money. Until profitability is absolutely certain, putting money into this company as an investor is a very risky speculation in my opinion.
You may be right. In which case, you’ll become a multimillionaire and my net worth won’t grow as much as it could’ve.
But I will not die broke.
The other possibility is that Emannow’s misleading us.
Might he have more shares at a much higher cost and sees no way of digging himself out of the hole that he’s dug?
Might he have more shares at a much higher cost and sees no way of digging himself out of the hole that he’s dug?
I’ll wait until I see the next earnings report rather than believe fantastic news a troubled shareholder.
feel free to go directly to the message board and read it for yourself!
https://cafepharma.com/boards/forums/revance-biotech.1254/#gsc.tab=0
The one rep I spoke with this past quarter (Q2 2024) hit her RHA Quota with 30 days still to go in the quarter. I truly hope Daxxify is now selling like it should!!!!! And she has attained 100% of quota with both products for the last 6 Quarters in a row,
Interesting claim, why u keep posting here if you have no interest on it
Its a copy/paste from cafepharma post last month. Nothing more, nothing less.
I don’t own and have never owned RVNC.
… neither long nor short.
I haven’t completely lost any interest whatsoever in RVNC
… But I doubt that I will see anything in the next earnings report that will convince me to put any money at risk.
At least we know he is long so make sense for him to post bullish message here
How about you?
…. That’s one possibility.
The other possibility is that Emannow’s misleading us.
Might he have more shares at a much higher cost and sees no way of digging himself out of the hole that he’s dug?
I’ll wait until I see the next earnings report rather than believe fantastic news a troubled shareholder.
I hope it’s true. It’s just too far-fetched for me to believe it at this point in time.
Emannow, let's hope what you've just reported is representative of the sales force as a whole.
Revance Sales Rep: June 23 2024
Do you see a lot more demand for Daxxify or relatively steady?
Both! “the launch” accounts needed a year to figure it out and realize they cant underdose and split a vial between 3 patients (being cheap) so they are coming around and reordering. New customers are fed up with Allergan and their “new pricing” pressure so calling to get daxxify on their shelves instead. injectors are learning the competitive toxin reps were bad mouthing daxxify and now trying it a year later and they love it. My territory is doing triple YTD. leadership may suck but the product is superior, especially when they don't “water it down” and hyper dilute..
Erica Jordan on DAXXIFY
https://www.instagram.com/reel/C8-k8YjxHzw/?igsh=OHljeXNpa2Q2dzFt
FWIW: Seeing a plethora of Botox discount offers on instagram.
Erica Jordan on The Technology of Beauty
Huge bullish falling wedge on weekly chart. If this week it closes higher than last week low of $2.3. I am in for $20K bet.
Well at least they didn’t cancel their plans lol
Not sure if that makes me feel any better.
Thank you! Not sure if that makes me feel any better
Very unusual indeed
Really hard to understand what’s going on
Are competing companies really messing around?
The insider buys reported today are limited in size because they are from the company’s Employee Stock Purchase Plan—see the footnotes:
https://www.sec.gov/Archives/edgar/data/1479290/000147929024000104/xslF345X05/wk-form4_1719956853.xml
https://www.sec.gov/Archives/edgar/data/1479290/000147929024000103/xslF345X05/wk-form4_1719956817.xml
... market cap. of less than 1 x annual sales. For a pharma company with a block-buster in the making - unheard off.
How much further can this stock drip down.? There are 5-6 weeks before the second quarter earnings announcement and if we get zero news between now and then could we see $2 by the first of August ?
RVNC should move higher as we approach 2nd Qtr earnings report in August. Looking for 1st Daxxi approval in China, update on CD path in US and significant progress in aesthetics sales.
I too suspect some bigger firms will try to buy out RVNC during this uncertain period. But the gap between current EV and actual value will be too great for RVNC and the acquirer to strike a deal I would think.
A partnership with significant upfront cash and tiered royalty would be more likely I suspect. I hope that's why no insider buying yet.
thetechnologyofbeauty on Youtube hosted by Grant Stevens, MD
NEXT TUESDAY July 2, 2024, on The Technology of Beauty… we welcome Erica Jordan of Revance to the show.
As the Chief Commercial Officer at Revance, Erica is responsible for developing and executing growth strategies for the aesthetics and therapeutics markets. She has over 20 years of experience in commercial and general management in the med-tech, biotech, and dental industries, working for leading companies including GE, Siemens, Philips, and Envista.
Show me three quarters of taking consistently growing market share and this one will be under someone else’s umbrella.
This is 8x current valuation, excluding debt. Times change, Last raise at 6$ caused 20% dilution. At some point you need to accept the path of least resistance. Daxy needs a daddy with strong arms, that can play the distance.
For therapeutics, the off-label payers approval is quite high. This is very unusual and all based on cost savings, as a lot of them see no differentiation vs botox.
Daxy is clearly differentiated, and its cheaper. Once they realize this, more and more barriers should be lifted.
Can't see the board not agreeing with anything near 20 per share., which will still be far below long term fair value.
If it is far below fair value I would hope they are smart enough to say no. I agree with the rest of that post. Just sit back and wait.
Interest rates are the same forall. Higher cost of refinancing shouldn't matter if trajectory to break even is clear. Company is trading at less than 1x forward sales and about 1x this year sales. Whether they pull break even in 25 or 26 shouldn't matter. Daxy will be the best Bont out there for at least another decade. Sooner or later, potential will be realized, and considering current valuation, i see them very vulnerable for a +2b take over. Can't see the board not agreeing with anything near 20 per share., which will still be far below long term fair value.
So this drive down on bancrupty concerns and nog being able to refinance the debt, is one of the dumbest, i've ever seen.
Agree, only a few expect they can close the gap by 2025, zero trust
As many said, most are in show me the money mode
At current val, all hinges on company closing the gap to profitability asap. Worst case, management can't meet the break-even guidance by Q4 '25 as promised. But that gap will most certainly have narrowed very significantly. So this drive down on bancrupty concerns and nog being able to refinance the debt, is one of the dumbest, i've ever seen.
Another low volume take down day
Insiders need to step up to put confidence back
Or we will have wait for sales numbers to come in nicely
We need about 10 days in a row of that kind of increase.
Sure….obviously those of us that actually purchase product will get end of quarter sales pitches. It felt a little different this Q…..Allergan reached out more than usual. What that means….I’m not exactly sure. But I have some guesses.
Got messages from most of the toxin reps the past couple hours. Trying to close out the quarter strong :)
Sure….obviously those of us that actually purchase product will get end of quarter sales pitches. It felt a little different this Q…..Allergan reached out more than usual. What that means….I’m not exactly sure. But I have some guesses.
I think we all got that Foley made some mistakes - the clear one for me was OPUL but at least he used shares for that deal.
But the question now is
Does $RVNC worth $500mm with all those mistakes Foley made PLUS Foley stays as the CEO for the foreseeable future?
If not, sell out and move on.
If yes, maybe add some or hold the bag for a little longer.
For me, I am holding.
[OT]—By the way Mitch Gold bounced back and sold the next company he was leading for 5-6 billion dollars.
Unfortunately with a silent Board of Directors, an investors relations group that disappeared, and CEO that has made MANY mistake Long time shareholders have grown frustrated. Perhaps dew you remember the many back and forths regarding Dendreon
and Mitch Gold.. The circumstances may have been different but the passion of the shareholders is much the same.
Foley has dug himself a huge hole and all the shareholders are hoping he finds a way out before the time runs out.
By the way Mitch Gold bounced back and sold the next company he was leading for 5-6 billion dollars.
Dew, if you check my past posts, i wrote about the Premium Pricing Strategy and why it was a failure. I wrote about the No Advertising Price Policy and why if was a failure. I wrote about the Marketing Team and why they were a failure. Foley has made at least half a dozen terrible leadership decisions in 18 months...seems like he makes one every 3 to 4 months....I would LOVE to see Foley turn RVNC Around...probably more $$$$ than you.
I have been involved with Aesthetic Marketing for over 20 years...Foley just keeps making bad decisions and then has to make more adjustments to try and fix the issues caused by the bad decisions.
Everyone you talk to, says the same thing about RVNC...Great products, Terrible Leadership!!!
Thanks for stating the obvious. Sales reps in every industry try to close out quarters strong.
Regarding Mark Foley, I have nothing to add to what I have previously posted. To re-iterate: Foley has made mistakes, but he has taken actions to rectify them. I don’t see any benefit to RVNC and its shareholders from replacing Foley. To the contrary, I think changing CEOs now could be disruptive and counterproductive.
Mark Foley obviously never took any Executive Marketing Management Courses...Foley brought CoolSculpting to a positive cash flow with NO COMPETITION and sold it to Allergan for $2.4 Billion. Total Con Job! CoolSculpting is a total Dog! Now Foley is in a completive market with an excellent product which wins every award and the Con Man Foley and is over his head!!! Foley has no clue who the Daxi target market is and still thinks "Injectors" are the "Target Consumer".
Foley thinks if he makes the injectors more profit, they will switch their patients to Daxi...WRONG...Injectors are reseller who are at the mercy of the aesthetic patient and kiss every patients butt hoping the patient will return to them and it costs an injector money (time) to switch a patient to Daxi. Cosmetic Injectors are all about the $$$$. Why does Allergan market directly to the aesthetic patient, everyday? Injectors are 100% aware that Allergan is squeezing their net profit out of Botox but "Change" is scary and Allergan keeps whispering in their ear, that "Botox will make the "practice" more profit." Allergan knows Daxi is much more profitable to the injector and is trying to confuse the injectors with "Practice" profit....Just so you know, typically, Toxin revenue is 50% to 60% of a practice's total annual revenue....what Allergan is telling the practice is 100% false. Foley waisted hundreds of millions and now WS see liabilities as greater than assets....TROUBLE...SP has dropped weekly.
FOLEY truly needs to understand medical marketing in a mature competitive market with a product which has 3 competitive advantages and is sold through a reseller as an annuity procedure. Offer the new product with 3 competitive advantages at the same price as the current market leaders. Establish market share and sell the company to a BIG Boy who will take it to the next level!
Educate the medical patient about the 3 competitive advantage and the $$$ they will save when using Daxi versus a 3 month toxin. Injectors who want to grow their Daxi patient base should be allowed to advertise their Daxi price on the the Daxi Injector Finder...love seeing injector pages listing...Botox $14 per unit, Daxi $7 per unit....now the patient will want to try the $7 per unit product which will give them the additional 3 benefits for the same price as Botox ( 2 to 1 units).Fast, Last and the Look! Patients will never go back to Botox!!! RVNC should be encouraging every unit pricing practice to advertise their Daxi this way!
Foley is clueless!
Mark Foley is Fxxxking Idiot!
He has made terrible decisions, one after another and is solely responsible for the SP and what has happened to RVNC.
Dew, do you still support Foley as your Man?
Revance Therapeutics, Inc. Common Stock (RVNC) Short Interest
Settlement Date Short Interest Avg. Daily Share Volume Days to Cover
06/14/2024 14,352,615 1,414,819 10.144488
05/31/2024 12,763,394 2,082,760 6.128116
05/15/2024 12,490,424 2,432,279 5.135276
Followers
|
152
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8276
|
Created
|
02/09/14
|
Type
|
Free
|
Moderators DewDiligence |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |